Roivant's mosliciguat hits all PHocus endpoints: PVR -56.3%, 6MWD +35.2m in PH-ILD

Roivant Sciences Ltd.

PHocus Phase 2 met primary endpoint: placebo-adjusted PVR reduction -56.3% (p<0.0001) at Week 16 in PH-ILD
Secondary endpoints met: 6MWD +35.2m (p=0.0027), NT-proBNP -53.2% (p=0.0002) at Week 16
Week 24 exploratory: 6MWD +52.7m, NT-proBNP -75.9% (both nominal p<0.0001)
Cough lower than placebo (12.1% vs 18.2%); favorable safety profile
Phase 3 PHrontier initiated (~375 patients); results presented at ERS 2026

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.